LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
105.07
-0.75 (-0.71%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close105.82
Open106.02
Bid0.00 x 1400
Ask0.00 x 800
Day's Range104.72 - 106.13
52 Week Range73.69 - 106.38
Volume2,775,584
Avg. Volume3,648,667
Market Cap107.078B
Beta0.43
PE Ratio (TTM)N/A
EPS (TTM)-0.14
Earnings DateOct 23, 2018
Forward Dividend & Yield2.25 (2.13%)
Ex-Dividend Date2018-08-14
1y Target Est97.13
Trade prices are not sourced from all markets
  • Should you trade or fade this week's biggest winners?
    CNBC Videos4 days ago

    Should you trade or fade this week's biggest winners?

    Trade or fade the week's big winners? The Fast Money traders weigh in. With CNBC's Melissa Lee and the Fast Money traders, Brian Kelly, Gina Sanchez, David Seaburg and Dan Nathan.

  • Merck Gets FDA Nod for Keytruda Lung Cancer Label Expansion
    Zacks20 hours ago

    Merck Gets FDA Nod for Keytruda Lung Cancer Label Expansion

    Merck (MRK) gets FDA approval to include overall survival data from a key late-stage lung cancer study, KEYNOTE-189 study, on the label of its PD-L1 inhibitor, Keytruda.

  • A Look at Teva Pharmaceutical’s Valuation Multiples in August
    Market Realist20 hours ago

    A Look at Teva Pharmaceutical’s Valuation Multiples in August

    On August 17, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 8.5x, compared to the industry average PE of 12.1x. The company’s forward EV-to-EBITDA1, which is a capital structure–neutral valuation measure, is 10.8x. A stock’s forward PE ratio is calculated by dividing its current stock price by the next-12-month earnings estimate of the company.

  • Recent Developments at Allergan
    Market Realist20 hours ago

    Recent Developments at Allergan

    Allergan (AGN) is developing a variety of products through internal programs as well as in collaboration with other companies. A few of the products it currently has under development are Cenicriviroc, Atogepant, Bimatoprost SR, Ubrogepant, Abicipar, Rapastinel, and Sarecycline.

  • Amgen’s Product Performance in Q2 2018
    Market Realistyesterday

    Amgen’s Product Performance in Q2 2018

    Amgen’s (AMGN) product portfolio includes the blockbuster drugs Prolia, Enbrel, Neulasta, Xgeva, Aranesp, Sensipar/Mimpara, Kyprolis, and Epogen. Blockbuster drug Neulasta (pegfilgrastim) reported a 1% rise in revenue to $1.10 billion during the second quarter compared to ~$1.09 billion in the second quarter of 2017.

  • Drugmakers Extend Summer Rally as Markets Regain Footing
    Bloomberg2 days ago

    Drugmakers Extend Summer Rally as Markets Regain Footing

    Major pharmaceutical companies are partying like it’s 2001. U.S. drugmakers including Pfizer Inc., Eli Lilly & Co., and Merck & Co. are seeing their share prices balloon to the highest levels in more than 16 years as investors rotate in after second-quarter results proved stronger than expected. Impressive earnings paired with waning concerns about potential Trump administration actions on drug pricing could be helping to draw generalist investors in a bit of a “catch up trade,” according to Credit Suisse analyst Vamil Divan.

  • Allergan’s US General Medicines Segment in Q2 2018
    Market Realist2 days ago

    Allergan’s US General Medicines Segment in Q2 2018

    Allergan’s (AGN) US General Medicines segment includes women’s health products, central nervous system products, anti-infective products, gastrointestinal products, and diversified brands.

  • Non-Opioid Pain Therapy Market Opportunity for Teva
    Market Realist2 days ago

    Non-Opioid Pain Therapy Market Opportunity for Teva

    On August 16, Teva announced positive top-line data for its NGF-inhibitor Fasinumab, which is being developed in collaboration with Regeneron. Teva’s stock price rise was also boosted by the FDA approval of Teva’s generic version of EpiPen, which we covered in FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%. Teva also has Fremanezumab in its product pipeline, which is expected to be a key growth driver for the company and is being developed for the treatment of migraines.

  • Lilly (LLY) Hits 52-Week High, Can the Run Continue?
    Zacks5 days ago

    Lilly (LLY) Hits 52-Week High, Can the Run Continue?

    Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Benzinga5 days ago

    The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 16) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Eli Lilly And ...

  • Investopedia6 days ago

    Eli Lilly's Overbought Stock Poised to Fall 15%

    Eli Lilly and Co.'s ( LLY) stock has jumped by more than 16% since the middle of July and by nearly 24% in 2018. The stock is poised to plunge 15% in the coming weeks, based on technical analysis. Eli Lilly's stock broke out following better-than-expected quarterly results and guidance, rising above a long-term technical resistance level around $88.50.

  • A Look at the Performance of Bausch Health’s Ortho Dermatologics
    Market Realist6 days ago

    A Look at the Performance of Bausch Health’s Ortho Dermatologics

    Bausch Health Companies’ (BHC) wholly-owned subsidiary Ortho Dermatologics generated revenue of $142.0 million in the second quarter compared to $162 million in the second quarter of 2017, reflecting a ~12% YoY (year-over-year) fall.

  • The Wall Street Journal6 days ago

    [$$] Karuna Appoints Steven Paul as CEO

    Karuna Pharmaceuticals Inc., which is developing treatments for schizophrenia and other neurological conditions, has appointed Chairman Steven Paul as chief executive.

  • What Does Nektar Therapeutics’ Valuation Trend Indicate?
    Market Realist7 days ago

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY). 

  • Elanco Animal Health Announces Pricing of $2.0 Billion of Senior Notes
    PR Newswire7 days ago

    Elanco Animal Health Announces Pricing of $2.0 Billion of Senior Notes

    Elanco will place the net proceeds of the Offering into escrow, to be released upon either the completion of its previously announced, anticipated initial public offering (IPO) or a special mandatory redemption, which would occur if the IPO does not take place, or Lilly otherwise determines that the IPO will not take place, by June 30, 2019. Elanco intends to pay the net proceeds of the Offering as part of the consideration to Lilly.

  • Analyzing Nektar Therapeutics’ Financial Performance
    Market Realist8 days ago

    Analyzing Nektar Therapeutics’ Financial Performance

    Nektar Therapeutics (NKTR) generated revenue of $1.09 billion in the second quarter compared to $34.59 million in the second quarter of 2017. 

  • Pfizer Is Expected to Report Modest Revenue Rise in Fiscal 2018
    Market Realist8 days ago

    Pfizer Is Expected to Report Modest Revenue Rise in Fiscal 2018

    In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 revenue guidance from the previously projected range of $53.5 billion–$55.5 billion to $53.0 billion–$55.0 billion, mainly to account for the unfavorable foreign currency fluctuations from mid-April 2018 to mid-July 2018. Analysts have projected Pfizer’s fiscal 2018 revenues to come in around $54.2 billion, which would be a year-over-year (or YoY) rise of approximately 3.1%. Merck (MRK), Eli Lilly (LLY), and Novartis (NVS) are expected to report revenues close to $42.4 billion, $24.3 billion, and $52.4 billion, respectively, in fiscal 2018.

  • Novo Nordisk’s Fast-Acting Insulins: A Performance Overview
    Market Realist8 days ago

    Novo Nordisk’s Fast-Acting Insulins: A Performance Overview

    In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, reflecting a ~2% YoY (year-over-year) growth in local currencies.

  • Mylan Launches First Adcirca Generic, Stock Moves Up
    Market Realist8 days ago

    Mylan Launches First Adcirca Generic, Stock Moves Up

    Today, Mylan Pharmaceuticals (MYL) announced the launch of tadalafil tablets USP (20 mg) in the United States. The drug is the first generic version of Eli Lilly’s (LLY) Adcirca (tadalafil) approved by the FDA.

  • Can Victoza Continue to Boost Novo Nordisk’s Revenue Growth?
    Market Realist9 days ago

    Can Victoza Continue to Boost Novo Nordisk’s Revenue Growth?

    Novo Nordisk’s (NVO) Victoza generated revenues of 11.7 billion Danish kroner in the first half of 2018 compared to 11.5 billion Danish kroner in the first half of 2017, a ~2% YoY (year-over-year) growth and a ~12% YoY growth in local currencies.

  • Novo Nordisk: A Financial Overview after the First Half of 2018
    Market Realist9 days ago

    Novo Nordisk: A Financial Overview after the First Half of 2018

    Novo Nordisk (NVO) reported net revenues of 54.3 billion Danish kroner in the first half of 2018 compared to 57.1 billion Danish kroner in H1 2017. That’s a ~5% YoY (year-over-year) decline.

  • Here's Why Lilly (LLY) Stock is Up 15% Since Q2 Earnings
    Zacks9 days ago

    Here's Why Lilly (LLY) Stock is Up 15% Since Q2 Earnings

    Eli Lilly's (LLY) stock is up 15% since announcement of earnings in July. Let us have a look at the reasons for the same.

  • Eli Lilly Stock History
    Motley Fool12 days ago

    Eli Lilly Stock History

    Here's how this company became a biopharma giant, and what could be in store next for investors.

  • Analysts’ Recommendations for Pfizer on August 6
    Market Realist13 days ago

    Analysts’ Recommendations for Pfizer on August 6

    Analysts expect Pfizer’s (PFE) adjusted EPS to be $2.99 on revenue of $54.3 billion in 2018, a 3.4% rise compared to $52.5 billion in 2017. Analysts also expect a 10.9% rise in the company’s adjusted net income during 2018, mainly due to a fall in its selling, general, and administrative expenses as well as its lower research and development expenses as a percentage of its sales.

  • Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates
    Zacks13 days ago

    Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates

    Celldex (CLDX) reports narrower-than-expected loss in Q2. Revenues fell due to reduced contract revenues.